Commercial insight into the pharma and biotech sector.

EvaluatePharma & EP Vantage in the Press

 January 2012

Pharma's niche focus spurs US aid for antibiotics - The Associated Press, January 25, 2012

"...Drugs worth a mammoth $255 billion in global annual sales are set to go off patent before 2016, according to EvaluatePharma Ltd., a London research firm...." more...

 December 2011

5 Medical Advances Predicted for 2012 - MyHealthNewsDaily, December 30, 2011

"...blockbuster drugs losing their patents in 2012 include Viagra, Seroquel and Lexapro, according to the industry analyst firm EvaluatePharma..." more...

'Double-Dip' Blow Could Strike Big Pharmas in 2012 - CNBC.com, December 27, 2011

"...Patent expiries are set to cost pharmaceutical firms $54 billion in sales between 2011 and 2012, with the cost reaching over $255 billion by 2016, according to EvaluatePharma..." more...

Frazier defends R&D investment and attacks price pressure - InPharm, December 14, 2011

"...a new regulatory submission would represent a remarkable turnaround for the drug [Mylotarg], which generated $83 million in 2009, according to EvaluatePharma data..." more...

Why Did My Stock Just Die? - The Motley Fool, December 12, 2011

"...one study by the researchers at EvaluatePharma suggests that the higher the level of confidence shown (as represented by big, upfront payments) the greater chance a drug has of success..." more...

Pfizer seeks 2nd chance for cancer drug Mylotarg - FiercePharma, December 12, 2011

"...Patients newly diagnosed with acute myeloid leukemia who received Mylotarg with chemotherapy lived for 25 months after treatment, compared with 15 months for those given chemotherapy alone..." more...

Pfizer's Failed Blood Cancer Drug Shows Benefits in Study of New Patients - Bloomberg, December 10, 2011

"...Patients newly diagnosed with acute myeloid leukemia who received Mylotarg with chemotherapy lived for 25 months after treatment, compared with 15 months for those given chemotherapy alone...

The study results may presage new life for what was an $83 million product in 2009, according to EvaluatePharma..." more...

Drugmakers Go From Abundance To Scarcity - Pharmalot, December 2, 2011

"...a group of analysts at the Oliver Wyman consulting firm decided to look at pharma life before and after the Vioxx withdrawal...forecasts were obtained from EvaluatePharma..." more...

 November 2011

Glaxo scientists 'live or die' in research overhaul - Bloomberg, November 30, 2011

"...The average value of new drugs approved in the last five years fell 25 percent from the previous five-year period, analysts at EvaluatePharma Ltd. estimate..." more...

The changing of the guard - Q3 round up - InPharm, November 25, 2011

"...Analysts at EvaluatePharma forecast that the loss of the $12 billion a year from Lipitor will knock Pfizer of its perch as the biggest firm by revenue....." more...

Five steps toward a revitalized pharmaceutical supply chain - strategy+business, November 14, 2011

"...the total number of new drugs approved by the US Food and Drug Administration fell to 28 from 33, according to market analyst EvaluatePharma...." more...

Merck highlights updated pipeline - InPharm, November 11, 2011

"Analysts at EvaluatePharma predict Merck will slip down the pharma league ... EvaluatePharma say that Merck will “struggle to grow its drug business” in the coming years..." more...

Sanofi targeting further acquisitions - Zenopa, November 4, 2011

""Our growth platforms again achieved double digit growth and more than compensated for generic erosion," Mr Viehbacher commented. Analysis from EvaluatePharma has said Sanofi is on course to replace Pfizer as the world's biggest pharmaceutical group..." more...

Sanofi could be top by 2012 - Pharmaceutical Technology Magazine (blog), November 4, 2011

"Pfizer, meanwhile, will drop to third place, and is likely to remain there for the foreseeable future, according to analysis firm EvaluatePharma. EvaluatePharma expects Pfizer's prescription and over-the-counter (OTC) sales to drop to $49.8 billion in 2012..." more...

Analysts predict Sanofi surge past Pfizer - Drug Discovery & Development, November 3, 2011

"Sanofi is expected to retain the top spot until at least 2016 with Pfizer relegated to third place, behind Novartis, toppled by the loss of mega-blockbuster drug Lipitor, consensus sales forecasts from EvaluatePharma show...." more...

Sanofi 'set to become world's biggest drugmaker' - Zenopa, November 3, 2011

"Analyst firm EvaluatePharma said the French company is on course to replace Pfizer at the top of the pile, with the current leader slipping to third place behind Novartis. The study also predicted that Sanofi will retain its position at number one until at least 2016..." more...

Pfizer could fall from No. 1 spot - Investor's Business Daily, November 2, 2011

"EvaluatePharma predicted that the looming loss of patent protection for Pfizer's cholesterol-fighting drug Lipitor will undermine future sales, causing the leading drugmaker — based on sales — to fall behind Sanofi (SNY) of France and Swiss-based Novartis (NVS)..." more...

Generic Lipitor may soon be coming to a drugstore near you - Business Insider, November 2, 2011

"...EvaluatePharma predicted that Pfizer would be knocked from its top spot in the pharmaceutical market by current No. 2 Sanofi-Aventis as soon as its patent for Lipitor dries up at the end of November..." more...

And The World’s Largest Drug Maker Will Be… - Pharmalot, November 2, 2011

"Sanofi is expected to become the No. 1 drugmaker next year and stay on top until at least 2016, by which time Pfizer will slide to third place, behind Novartis, according to the latest calculation by EvaluatePharma..." more...

Sanofi to become world's biggest drug maker - InPharm, November 2, 2011

"Sanofi is now expected to take its place at the top, followed by Novartis, Pfizer and GlaxoSmithKline, according to industry analysts at EvaluatePharma. EvaluatePharma are projecting annual sales growth of 4% over the next four years for Sanofi..." more...

Pfizer could lose No. 1 global sales ranking to Sanofi next year, report finds - Drug Store News, November 1, 2011

"[EvaluatePharma] attributed the French drug maker's [Sanofi's] rise to its mergers and acquisitions activity, particularly its purchase earlier this year of U.S. biotech manufacturer Genzyme Corp..." more...

Pfizer May Bring Over-the-Counter Lipitor to Market, CEO Says - Bloomberg, November 1, 2011

"The loss of Lipitor’s patent-protected revenue will relegate the New York-based company [Pfizer] from its place atop the pharmaceutical world, where it leads all competitors in drug sales, EvaluatePharma Ltd. said...In 2012, Paris-based Sanofi will hold the top spot, followed by Basel, Switzerland-based Novartis AG, and Pfizer in third..." more...

Sanofi set to rev past Pfizer in pharma rankings - FiercePharma, November 1, 2011

"After Lipitor falls off patent, Pfizer will fall out of first place in the pharma universe. Who'll take the crown then? Sanofi, thanks to its $20 billion merger with Genzyme. According to EvaluatePharma, Sanofi ($SNY) will hang onto the top slot at least till 2016, with the Swiss drugmaker Novartis ($NVS) trailing close behind...." more...

Sanofi poised to lead pharma sales in 2012 - PMLive.com, November 1, 2011

"EvaluatePharma said it expects the French pharma company [Sanofi] to take the top spot in 2012 and then hold it for the next four years, thanks to the mergers and acquisitions it has made in recent years...." more...

Sanofi to topple Pfizer as sales league leader next year - Pharma Times online, November 1, 2011

"After nine years as the world’s biggest drugmaker, Pfizer is going to be knocked off its perch in 2012 by Sanofi.

That is the conclusion from consensus sales forecasts made by research company EvaluatePharma..." more...

Prevnar and Lyrica lift Pfizer results - InPharm, November 1, 2011

"Analysts at EvaluatePharma forecast the loss of the $12 billion a year from Lipitor will knock Pfizer of its perch as the biggest drug maker by revenue. Sanofi is predicted to take the top spot next year, with Pfizer relegated to third place. ..." more...

 October 2011

The best British big pharma stock to buy now - MoneyWeek, October 28, 2011

"...between 2011 and 2016, $255bn-worth of annual sales of the world's top-selling drugs will go off patent, says researcher EvaluatePharma..." more...

Pfizer edges toward Lipitor patent cliff as exclusivity extensions near end - Genetic Engineering News, October 18, 2011

"Lipitor accounts for a sizeable share of the $250 billion in aggregate sales estimated by EvaluatePharma for the prescription drugs heading over the patent cliff..." more...

Prepare your plan for the price of biologics - The Economic Times, October 13, 2011

"According to EvaluatePharma, by 2016, 48% of global revenues of the top 100 drug products will be from biotechnology - bio-engineered vaccines and biologic drugs..." more...

 September 2011

Why are some antidepressants more expensive than others? - io9, September 29, 2011

"...analyses published in June of this year by EvaluatePharma — a leading pharmaceutical and biotech analysis firm — estimate that patent expirations between 2010 and 2016 will result in over $113 billion in sales being lost to generic substitutions." more...

Plunging off the patent cliff - Healthcare Global, September 29, 2011

"...EvaluatePharma...estimated that overall, the pharmaceutical industry is at risk of losing $250 billion in sales of drugs between now and 2015." more...

 August 2011

Prepare your plan for the price of biologics - Benefits Canada, August 17, 2011

"In 2009...EvaluatePharma suggested that in 2014, six of the top 10 drugs will be biologics." more...

How Novartis Plans to Avoid the 'Patent Cliff' - BusinessWeek, August 4, 2011

"Drugs with $139 billion in combined annual sales will be going off patent in the next five years, according to researcher EvaluatePharma..." more...

 July 2011

J&J or Novartis? - Motley Fool, July 28, 2011

"...only Pfizer (NYSE: PFE ) and Merck (NYSE: MRK ) currently spend more [on R&D than J&J], and by 2016, Novartis will surpass them, too, according to Evaluate Pharma..." more...

As top drug patents expire, pharma revenues become dire - Cardiovascular Business , July 26, 2011

"Pfizer is set to undergo the biggest loss when Lipitor, a cholesterol lowering drug, loses its expiry worth $11 billion in November, EvaluatePharma reported. "The sector is facing an unprecedented period of patent expiries when mega-blockbusters, including Lipitor, Plavix and Zyprexa, will all be exposed to cheap, generic drugs," EvaluatePharma said..." more...

Expiring drug patents to lower costs - Benefits Canada, July 26, 2011

"According to AP, UK-based research firm EvaluatePharma Ltd. estimates drugs totaling more than $250 billion in global sales annually are scheduled to lose patent protection by 2016..." more...

Popular Drug Prices to Drop Significantly - 13WHAM-TV, July 26, 2011

"... According to EvaluatePharma, a London research firm, the drugs going off-patent between now and 2016 amount to $255 billion in global sales annually..." more...

Major Drugs to Lose Patents Making Way for Generic Drugs - TopNews New Zealand, July 26, 2011

"... If EvaluatePharma, a London research firm, is to be believed, companies losing their drug patents between now and 2016 would be at a loss of $255 billion in global sales annually..." more...

New Generic Drugs Mean Lower Prices - National Journal, July 26, 2011

"...According to London research company EvaluatePharma Ltd., pharmaceuticals totaling about $255 billion in global annual sales will go off patent, including drugs for blood pressure, asthma, diabetes, depression, cholesterol, HIV, and bipolar disorder..." more...

Generic Drug Blitz to Lower Prescription Costs - ThirdAge, July 25, 2011

"...When generic brands go on sale, costs will plummet and the drugs will become more widely available to patients and health care companies, London-based research firm EvaluatePharma Ltd. said..." more...

Prescription Drug Prices Set To Tumble As Brand Name Drug Patents Expire - The Inquisitr, July 25, 2011

" According to EvaluatePharma, between now and 2016 even more patents will expire with currently patented drugs going off patent to the tune of $255 billion annually..." more...

Drug Prices Will Soon Drop Worldwide - RedOrbit, July 25, 2011

"...EvaluatePharma Ltd said that between now and 2016, blockbuster drug patents worth about $255 billion in global annual sales will go off patent..." more...

Patents Expire for Big Name Drugs - The Scientist, July 25, 2011

"...the next five years will see the patent expiration for drugs that currently bring in about $255 billion each year in global sales, according to London research firm EvaluatePharma...." more...

Cost of Prescription Medicines to Crash Down - French Tribune, July 25, 2011

"According to EvaluatePharma, between this year and 2016, even more patents will expire. According to the Generic Pharmaceutical Association, the proportion of prescriptions filled with generic drugs gained 78% in 2010, up from 57% in 2004..." more...

Health Highlights - DoctorsLounge - July 25, 2011

"Over the next 14 months, patents on seven of the world's 20 best-selling drugs will expire, according to London-based EvaluatePharma Ltd..." more...

Drug prices to plummet in wave of expiring patents - Washington Times - July 25, 2011

"The magnitude of this wave of expiring drugs patents is unprecedented. Between now and 2016, blockbusters with about $255 billion in global annual sales will go off patent, notes EvaluatePharma Ltd...." more...

Expiring Drug Patents to Drive Prices Down of Medicines - International Business Times - July 25, 2011

"EvaluatePharma Ltd., a London research firm, notes that blockbuster medications with about $255 billion in global annual sales are set to go off patent..." more...

Prescription Drug Prices Take a Dive as Patents are Set to Expire -ThirdAge - July 25, 2011

"Between now and 2016, patents on blockbuster drugs with about $255 billion in global annual sales are set to expire, EvaluatePharma Ltd., a London research company..." more...

Drug prices to plummet in wave of expiring patents - Straits Times - July 25, 2011

"Between now and 2016, blockbusters with about US$255 billion (S$308 billion) in global annual sales are set to go off patent, notes EvaluatePharma, ...more...

Threat of Generic Copycat Comes Back to Nip at Teva - Wall Street Journal Today - July 25, 2011 [subscription only]

"Teva is the 13th-biggest drug maker by sales, according to EvaluatePharma, after Bristol-Myers Squibb Co. and ahead of Amgen Inc....

Drug prices to plummet in wave of expiring patents - San Jose Mercury News, July 24, 2011

"From now until 2016, blockbusters with about $255 billion in global annual sales are set to go off patent, notes EvaluatePharma, a London research firm..." more...

Pfizer breaks from merger mentality as others chase leads - Nature Medicine - July 7, 2011 [subscription only]

"...Over the next two years, patents will expire on more than a dozen blockbuster drugs with combined annual sales of about $50 billion, according to the research organization EvaluatePharma..." more...  [subscription only]

FDA Withdraws Approval for Roche's Avastin - ePT - the Electronic Newsletter of Pharmaceutical Technology - July 7, 2011

"Roche...refused FDA’s recommendation to voluntarily withdraw Avastin’s breast cancer indication - the first company to ever do so, according to a report from EP Vantage..." more...

R&D spending soars above value of new drugs - IBJ.com - July 5, 2011

"...EvaluatePharma, a London-based research firm...compared the value (calculated as future sales in today’s dollars) of products launched from 2008 to 2010 — which came out to be $70 billion per year. The value of R&D spending during the same period: $127 billion per year.

"'The Industry as a whole is not yet generating a return on R&D investment,' wrote Anthony Raeside, EvaluatePharma’s head of research." more...

 June 2011

Company news: EvaluatePharma and Citeline - Medical Marketing & Media - June 28, 2011

"Years after generic competition begins eroding Lipitor revenues (and RA biologic Humira overtakes it as the world's biggest selling drug), Pfizer will still be the industry's sales leader, but Sanofi and Novartis will run closely behind, according to EvaluatePharma's World Preview 2016." more...

Humira To Take Top Selling Drug Spot - Drug Discovery & Development - June 28, 2011

"Humira will assume Lipitor’s crown as the world’s biggest selling drug, while Pfizer will cling on to its ranking as the biggest seller of prescription medicines through to 2016, according to the World Preview 2016 report published by EvaluatePharma." more...

Seeking a sustainable pharmaceutical revenue stream? - Healthcare Packaging online, June 28, 2011

"...pharmaceutical and biotech analysis source EvaluatePharma says, "Lipitor’s patent expiry this year precipitates the steepest decline in the industry’s patent cliff" more...

Pharma Edges Toward 'Patent Cliff' - Wall Street Journal Online, June 15, 2011 [subscription only]

"...an estimated $250 billion in sales [of prescription pharmaceuticals, worldwide] is at risk through 2015, according to data from...EvaluatePharma." more... [subscription only]

Abbott Sued Over Claim Humira Caused Fungal Infection - Bloomberg.com, June 13, 2011

"Humira, with 2010 sales of $6.55 billion, is expected to become the world’s most lucrative drug by 2016, according to a forecast by research company EvaluatePharma." more...

 May 2011

Takeda denies $12bn Nycomed takeover reports - InPharm.com, May 13, 2011

"Industry analysts at EvaluatePharma said the purchase of the Swiss drugmaker, which is particularly strong in Latin America, Russia and the Middle East, would double Takeda’s sales in emerging markets, a target the Japanese firm set itself last year." more...

Pharma’s Surefire Formula: Simultaneous Optimization and Reinvention - Forbes.com, May 10, 2011

"According to a report from EvaluatePharma, more than $267 billion worth of sales are at risk for drugs makers Pfizer, Eli Lily, Merck and others. ..." more...

 April 2011

Abbott Labs Sued on Claim Humira Caused Lasting Nerve Damage - Bloomberg.com online, April 26, 2011

"Humira is expected to outsell [Roche's] Avastin cancer medicine by 2016 to become the world’s most lucrative drug, according to a May 2010 forecast by research company EvaluatePharma." more...

Beyond the cliff, dividends, M&A beckon for big pharma - Financial Post online, April 22, 2011

""...big pharma...companies are turning to the M&A market looking for acquisitions in order to bolster pipelines to offset lost revenues. Since late February there here been 10 announced deals, according to EvaluatePharma,"" more...

 March 2011

FDA approval counts sell R&D productivity short - EvaluatePharma - PharmaTimes online, Mar 15, 2011

"Counting the annual tally of drug approvals by the US Food and Drug Administration (FDA) consistently understates the true value of industry R&D productivity, argues research company EvaluatePharma." more...

R&D productivity measures consistently under-scored and under-valued, EvaluatePharma data reveals - EvaluatePharma.com, Mar 14, 2011

"Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows." more...

 February 2011

Big Pharma Patent Expirations To Sock 2012 US Drug Sales - Wall Street Journal Online, Feb 15, 2011 [subscription only]

"...research firm EvaluatePharma Ltd. estimates medicines now generating $133 billion in annual U.S. sales could become exposed to generic competition by 2016." more... [subscription only]

Pfizer slashes R&D - Nature Online, Feb 9, 2011

"London-based analysts EvaluatePharma expect patent expiries over the next three years to expose about two-thirds of Pfizer's total sales to competition from generics..." more...

The issue: Sales of biologic drugs -  AZ Fact Check (azcentral.com), February 7, 2011

"...[EvaluatePharma's] "World Preview 2016" [included a forecast] that biotechnology products will make up about 48 percent of the top 100 drugs in 2016..." more...

Pharma Patent Storm Gathering Strength -  LaboratoryEquipment.com, Feb 3, 2011

"A staggering $33.2B of sales will be exposed to low-cost generics in 2012 in the US alone, more than double this year's figure, an analysis by EP Vantage reveals...'" more...

2012, Real 'annus horribilis' for Patent Expiries - EvaluatePharma -  PharmaTimes.com, Feb 3, 2011

"EP Vantage adds that this means 'Pfizer's reign as the world's biggest drug maker will soon be over...'" more...

Pharmaceutical industry bracing for record patent expiries, EvaluatePharma data reveals -  EvaluatePharma.com, Feb 2, 2011

"Thirteen US blockbusters will lose patent protection over the next two years, data from EvaluatePharma show...'" more...

 January 2011

This is the sector to back for the next decade -  MoneyWeek, Jan 17, 2011

"...EvaluatePharma projects that biologics (genetically engineered drugs) will account for 50% of the top 100 drugs in 2014..." more...

 December 2010

AstraZeneca takes $445m hit to halt motavizumab licence application -  InPharm, December 22, 2010

"AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the company $445 million...

The company...said this will have no impact on its share earnings guidance for 2010. But the move is still a blow to the firm - motavizumab was forecast by analysts at EvaluatePharma to make over $5 billion a year by 2016..." more...

[note- in April 2010, EvaluatePharma calculated the NPV of motavizumab to AstraZeneca to be more than $5 billion.]

New Life Science Companies- Boston City TV (via YouTube), Dec 2, 2010

"Mayor Menino welcomes Evaluate Pharma and other new life science companies to Boston with a ribbon cutting ceremony. November 11, 2010.." more...

• Our Products 
• Our Clients
• About Us
• EvaluatePharma Alpha
• EP Vantage

Email this page to a colleague